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Abstract 
Objective: Bile acids (BA) participate in the maintenance of metabolic homeostasis acting 
through different signaling pathways. The nuclear BA receptor farnesoid X receptor (FXR) 
regulates pathways in BA, lipid, glucose and energy metabolism which become dysregulated 
in obesity. However, the role of FXR in obesity and associated complications, such as 
dyslipidemia and insulin resistance, has not been directly assessed.  
Research Design and Methods: Here, we evaluate the consequences of FXR-deficiency on 
body weight development, lipid metabolism and insulin resistance in murine models of 
genetic and diet-induced obesity. 
Results: FXR-deficiency attenuated body weight gain and reduced adipose tissue mass in both 
models. Surprisingly, glucose homeostasis improved due to an enhanced glucose clearance 
and adipose tissue insulin sensitivity. In contrast, hepatic insulin sensitivity did not change, 
and liver steatosis aggravated due to the repression of β-oxidation genes. In agreement, liver-
specific FXR-deficiency did not protect from diet-induced obesity and insulin resistance 
indicating a role for non-hepatic FXR in the control of glucose homeostasis in obesity. 
Decreasing elevated plasma BA concentrations in obese FXR-deficient mice by 
administration of the BA sequestrant colesevelam improved glucose homeostasis in a FXR-
dependent manner indicating that the observed improvements by FXR-deficiency are not due 
to indirect effects of altered BA metabolism.  
Conclusions: Overall, FXR-deficiency in obesity beneficially affects body weight 
development and glucose homeostasis.  
 
 
Keywords: FXR, bile acids, obesity, glucose homeostasis, insulin resistance, energy 
metabolism, triglyceride metabolism, bile acid sequestrants 
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Obesity is characterized by an excess of adipose tissue mass which predisposes to metabolic 
perturbations, including insulin resistance, hyperlipidemia and fatty liver, promoting the 
development of type 2 diabetes and cardiovascular disease. Dysregulation of various 
metabolic pathways in tissues such as adipose tissue, skeletal muscle, the pancreas and the 
liver lay at the basis of these metabolic complications, but the exact mechanisms are still not 
well understood (1). 
Nuclear receptors are ligand-activated transcription factors, which regulate gene expression 
by binding to specific response elements in the promoters of target genes. The farnesoid X 
receptor (FXR) is a key regulator of bile acid (BA) metabolism. By promoting BA efflux 
from the liver, inhibiting hepatic BA synthesis and intestinal absorption, FXR controls the 
enterohepatic cycling of BA (2). Additionally, FXR regulates lipid metabolism, insulin 
sensitivity and energy homeostasis (3). FXR activation lowers plasma and liver triglycerides 
by repressing sterol regulatory element binding protein (SREBP)1c-mediated hepatic 
lipogenesis (4) and by enhancing plasma triglyceride clearance via apolipoprotein (apo)CII 
induction (5) and apoCIII inhibition (6) in the liver, resulting in an increased lipoprotein 
lipase (LPL) activity. Consequently, FXR-deficient (FXR-/-) mice are dyslipidemic, displaying 
elevated plasma triglycerides, total and HDL-cholesterol (7-9).  
The characterization of FXR-/- mice further revealed an important function of FXR in the 
control of glucose homeostasis. FXR-/- mice are transiently hypoglycemic when fasted (8,10), 
exhibit a delayed intestinal glucose absorption (10) and a reduced hepatic glycogen content 
(10-12). Hepatic gluconeogenic gene expression is decreased in the absence of FXR (11-13) 
and induced upon FXR activation in vivo (14). Moreover, FXR-/- mice display peripheral 
insulin resistance with an impaired insulin signaling response in adipose tissue and skeletal 
muscle (8,13). Additionally, FXR may control adipose tissue biology. FXR-/- mice exhibit a 
decrease in adipose tissue mass with smaller adipocytes (8). Conversely, FXR activation in 
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vitro stimulates adipocyte differentiation (15) by promoting PPARγ activity and inhibiting the 
Wnt/β-catenin pathway (16).  
BA act as regulators of metabolic homeostasis also through FXR-independent pathways (17). 
Apart from FXR, BA have been reported to activate the G-protein coupled BA receptor 
(TGR5), the pregnane X receptor (PXR), the vitamin D receptor (VDR) or the formyl peptide 
receptor (FPR) (17). TGR5 activation by BA increases energy expenditure in thermogenic 
tissues by inducing deiodinase 2 (D2) (18) and improves glucose homeostasis by stimulating 
glucagon-like peptide 1 (GLP-1) secretion from intestinal L-cells (19,20). Hence, since FXR 
controls plasma BA concentrations, the metabolic actions of FXR can be due to direct FXR-
mediated and/or indirect BA-mediated effects (2). BA metabolism can be pharmacologically 
modulated by BA sequestrants (BAS), such as colesevelam, which bind BA in the intestinal 
lumen and interrupt their enterohepatic cycling. BAS lower plasma cholesterol levels by 
stimulating hepatic BA synthesis from cholesterol and increasing LDL receptor activity (3). In 
diabetic patients, BAS improve glycemic control (21), associated with an activation of the 
incretin system due to an enhanced GLP-1 secretion as shown in rodent models of diabetes 
(22,23). 
Studies on the metabolic function of FXR have so far been limited to lean FXR-/- mice. 
However, the role of FXR in the adaptation to obesity and its metabolic complications has not 
yet been assessed. To address this issue, we investigated the impact of FXR-deficiency in 
murine models of genetic (ob/ob) and diet-induced obesity. Our results show that FXR-
deficiency protects from excessive body weight gain in both models by reducing adipose 
tissue mass. Interestingly, hyperglycemia and glucose tolerance improved associated with 
improved peripheral glucose clearance and adipose tissue insulin sensitivity. Liver insulin 
sensitivity was not altered by FXR-deficiency and hepatic steatosis became even more 
pronounced associated with elevated plasma triglyceride levels and reduced expression of 
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genes implicated in β-oxidation. Furthermore, liver-specific FXR-deficient mice were not 
protected from diet-induced obesity and insulin resistance, indicating a role for non-hepatic 
FXR in the improvement of glucose metabolism. Finally, to assess the contribution of 
elevated plasma BA concentrations observed in FXR-deficient models of obesity, plasma BA 
levels were reduced by administration of the BAS colesevelam. Colesevelam treatment 
improved glucose homeostasis in genetic obesity only in the presence of FXR, indicating that 
the changes in BA concentrations are not responsible for the improved glucose homeostasis in 
obese FXR-deficient mice. Thus, selective FXR antagonism or elimination of ligands, e.g. by 
BAS, may be an interesting pharmacological option for the therapy of metabolic disorders 
associated with obesity. 
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Research Design and Methods 
Animals. All experiments were performed with the approval of the Institut Pasteur de Lille 
review board. Animals were housed in a 12h-light/12h-dark cycle and maintained on a 
standard chow (A03, SAFE). Unless stated otherwise, male mice were used for 
experimentation. FXR-/- (7) and FXR-floxed mice (7) were backcrossed for seven or ten 
generations, respectively, onto a C57Bl/6J background. FXR+/+ob/ob and FXR-/-ob/ob mice 
and lean littermates were generated by crossing FXR-/- and leptin-deficient mice (B6.V-
Lepob/J, Charles River). Liver-specific FXR-/- mice (FXRflox/floxAlb-Cre+/-=LFXR-/-) and 
wildtype littermates (FXRflox/floxAlb-Cre-/-=LFXR+/+) were generated by crossing FXR-floxed 
and Albumin-Cre recombinase expressing mice (C57BL/6-Tg(Alb-cre)21Mgn/J, Charles 
River). To study diet-induced obesity, mice received a high-fat diet (HFD) (D12492, Research 
Diets; 60% kcal fat) and controls a low-fat diet (D12450B, Research Diets; 10% kcal fat), 
20w-old FXR+/+ and FXR-/- mice for 20w and 10w-old LFXR-/- and LFXR+/+ mice for 9w. 
The BAS colesevelam (Daiichi Sankyo) was administered with the diet (2% in standard 
chow) ad libitum to 10w-old FXR+/+ob/ob and FXR-/-ob/ob mice for 3w. Body weight was 
monitored weekly. Fat and lean mass were determined by dual x-ray absorptiometry 
(Piximus, GE Medical Systems LUNAR). Food intake was estimated during 6 periods of 2d. 
Animals were sacrificed after a 6h-fast by cervical dislocation. Tissues were removed and 
snap-frozen in liquid nitrogen.  
 
Plasma parameters. Blood was sampled after a 6h-fast and parameters determined as 
followed: blood glucose (Accu-Check, Roche Diagnostics), insulin (Mercodia), non-esterified 
fatty acids (FFA) (Wako), triglycerides (Biomerieux), leptin (R&D Systems) and total BA as 
described (24). Lipoprotein profiles in plasma pools were generated by fast protein liquid 
Page 7 of 38 Diabetes
 7 
chromatography (FPLC; Superose 6 HR 10/30, Amersham GE Healthcare) with subsequent 
determination of triglycerides.  
 
Indirect calorimetry. Mice were housed individually in metabolic cages (Oxylet, PanLab) 
for 48h to measure O2-consumption (VO2) and CO2-production (VCO2). Energy expenditure 
was calculated as described (25). 
 
VLDL production. Mice were intravenously injected with 500mg/kg Tyloxapol (Sigma) 
after a 6h-fast and triglycerides were measured in plasma sampled as indicated.  
 
Assessment of glucose metabolism. For tolerance tests 1g/kg glucose or 2IU/kg insulin 
(Actrapid Penfill, Novo Nordisk), respectively, were injected intraperitoneally and blood 
glucose measured as indicated. The metabolic clearance rate (MCR) was determined by stable 
isotope dilution as described (26). To measure the insulin signaling response, tissues were 
harvested 10min after intraperitoneal injection of 1IU/kg insulin (Actrapid Penfill, Novo 
Nordisk) or 0.9% NaCl into overnight-fasted female mice. Serine473-phosphorylated Akt and 
total Akt protein expression (Cell Signaling Technology) were detected by Western Blot and 
signals quantified by GeneTool software (Syngene). Pancreas morphometry was analyzed as 
described (27). 
 
Quantitative RT-PCR (qPCR). Total RNA was isolated from tissue samples by 
GSCN/phenol/chloroform extraction (28) and reverse transcribed into cDNA (Superscript II 
kit, Applied Bioscience). QPCR was performed with the BrilliantII SYBR Green QPCR 
Master Mix (Agilent) and specific primers (Supplementary Table1) on a mx3005 (Agilent). 
Gene expression was normalized to 28S and the value in FXR+/+ob/ob samples set to 1. 
Page 8 of 38Diabetes
 8 
 
Lipidomics. Lipidomics analysis of adipose tissue was performed as described (29).  
 
Statistical analysis. All values are reported as means±SEM. Statistical significance was 
analyzed as indicated by 2way-ANOVA and Bonferroni posthoc test or Mann-Whitney test 
using Prism (GraphPad). Differences were considered significant when p<0.05. Partial least 
squares discriminant analysis (PLS/DA) was performed using Matlab, version 7.5 
(Mathworks) and PLS Toolbox, version 4.2 (Eigenvector Research). 
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Results 
FXR-deficiency attenuates weight gain in genetic obesity. 
As a first approach to assess the role of FXR in obesity, FXR-/- mice were crossed into the 
ob/ob background to produce FXR-/-ob/ob mice which were subsequently compared to 
FXR+/+ob/ob controls. 
The weight gain observed in FXR+/+ob/ob mice was significantly attenuated by FXR-
deficiency, already from 7w of age onwards (Fig.1A) (p<0.0001; 2way-ANOVA). Dual x-ray 
absorptiometry revealed a decrease in fat (22%) and less pronounced in lean (10%) mass of 
FXR-/-ob/ob mice (Fig.1B). Concordantly, the estimated food intake tended to decrease in 
FXR-/-ob/ob mice (15.5±1.1 vs. 18.9±0.8 kcal/d/mouse). Indirect calorimetry demonstrated 
that O2-consumption (VO2) and CO2-production (VCO2) were equally reduced in FXR-/-ob/ob 
mice compared to FXR+/+ob/ob controls (Fig.1C and 1D), resulting in nearly identical values 
for the respiratory quotient (data not shown). Consistent with the decrease in VO2 and body 
weight, calculated energy expenditure was lower in FXR-/-ob/ob than in FXR+/+ob/ob mice 
(7.1±0.3 vs. 8.7±0.7 kcal/d/mouse) even though the difference did not reach statistical 
significance. 
Overall, FXR-deficiency leads to a decreased storage of energy in form of adipose tissue 
resulting in a lower total body weight. 
 
FXR-deficiency improves glucose homeostasis in genetic obesity by increasing peripheral 
glucose disposal. 
Since lean FXR-/- mice develop peripheral insulin resistance (8,13), it was next assessed 
whether FXR-deficiency in obesity affects glucose homeostasis. In contrast to hyperglycemic 
FXR+/+ob/ob mice, FXR-/-ob/ob mice displayed normal blood glucose levels (Fig.2A) 
(p<0.0001; 2way-ANOVA). In addition, the hyperinsulinemia typically observed in 
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FXR+/+ob/ob mice was significantly reduced in the absence of FXR (Fig.2B). Concordant 
with the decreased hyperglycemia and hyperinsulinemia, glucose tolerance was significantly 
improved in FXR-/-ob/ob mice (Fig.2C), due to a combination of lower fasting glycemia and 
improved glucose handling as evident from the significantly smaller integrated area under the 
curve (iAUC) (Fig.2D). The MCR of glucose was further significantly improved in FXR-/-
ob/ob mice (Fig.2E) indicative of a higher glucose disposal in the periphery. In line, an insulin 
tolerance test showed that FXR-/-ob/ob mice are more insulin sensitive than FXR+/+ob/ob mice 
(Fig.2F and 2G) with a more drastic decline of blood glucose levels in response to the 
administered insulin bolus (p<0.0001; 2way-ANOVA). Insulin resistant FXR+/+ob/ob mice 
exhibited enlarged islets of Langerhans (Fig.2H, compare arrows) due to compensatory 
hypertrophy. In contrast, islets of FXR-/-ob/ob mice were significantly smaller likely (Fig.2I) 
reflecting the relieved metabolic pressure due to the improved insulin sensitivity. These 
findings indicate that, in contrast to lean mice, FXR-deficiency might improve glucose 
homeostasis in genetic obesity. 
 
Adipose tissue, but not hepatic insulin sensitivity is improved in FXR-/-ob/ob mice. 
To analyze the contribution of peripheral tissues and the liver to the improvement of insulin 
sensitivity, the phosphorylation of Akt, a key mediator of insulin’s metabolic action, was 
measured in response to an in vivo administered insulin bolus (Fig.3A). Akt phosphorylation 
was increased in adipose tissue of FXR-/-ob/ob compared to FXR+/+ob/ob mice (2.8x vs. 1.5x). 
In contrast, the response in skeletal muscle (4.5x vs. 4.8x) and liver (2.0x vs. 1.7x) was not 
different between both genotypes.  
Hepatic insulin resistance is often associated with a fatty liver (30). Since FXR regulates 
lipogenesis in lean mice (2), hepatic gene expression and lipid content were determined. No 
changes were seen in the mRNA expression of the key regulator of lipogenesis, SREBP1c 
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(Fig.3B). Expression of genes involved in FA synthesis were only modestly induced (ACC1, 
FAS, SCD1) in livers of FXR-/-ob/ob mice (Fig.3B). Nevertheless, the hepatic triglyceride 
content was doubled in the absence of FXR (Fig.3C). The expression of PPARα, a key 
regulator of FA oxidation, and CPT1A, which ensures the FA entry into the mitochondria, 
were significantly decreased in FXR-/-ob/ob compared to FXR+/+ob/ob mice (Fig.3B). 
Expression of ACC2, which indirectly inhibits CPT1A, was significantly higher, indicating 
that a reduced FA oxidation likely contributes to the increased steatosis in FXR-/-ob/ob mice. 
Thus, an improvement of adipose tissue insulin sensitivity seems to account for the observed 
changes in glucose homeostasis. Hepatic insulin sensitivity was not altered by FXR-
deficiency, even though liver steatosis increased. 
 
FXR-/-ob/ob mice exhibit hypertriglyceridemia due to an impaired intravascular triglyceride 
clearance. 
Since FXR-/-ob/ob mice display increased liver steatosis and reduced adipose tissue mass, it 
was tested whether this phenotype was associated with alterations in triglyceride or FA 
metabolism. Plasma FFA concentrations were not different between genotypes (Fig.4A). In 
contrast, plasma triglyceride levels were strongly elevated in FXR-/-ob/ob compared to 
FXR+/+ob/ob mice (Fig.4B). Analysis of the lipoprotein profile revealed that triglycerides 
were mainly increased in VLDL, but also IDL/LDL-sized particles (Fig.4C). To determine 
whether this was due to altered hepatic triglyceride secretion, plasma triglyceride 
accumulation was assessed after inhibition of intravascular lipolysis (Fig.4D). Hepatic VLDL 
production was similar between FXR-/-ob/ob and FXR+/+ob/ob mice, suggesting that an 
impairment of intravascular triglyceride clearance by LPL underlies the elevated plasma 
triglycerides. Consistently, hepatic mRNA levels of apoCII and apoAV, activators of LPL, 
were markedly repressed (by 65% and 74%, respectively) in FXR-/-ob/ob mice (Fig.4E).  
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Hence, the repression of plasma triglyceride clearance regulators combined with the reduction 
of adipose tissue mass might result in the development of hypertriglyceridemia.  
 
Total but not liver-specific FXR-deficiency protects from diet-induced obesity and insulin 
resistance. 
To assess the impact of FXR-deficiency in obesity in a model expressing functional leptin, 
lean FXR-/- and FXR+/+ mice were fed a HFD for 20w. Whereas FXR+/+ mice rapidly gained 
weight upon HFD-feeding, body weight remained significantly lower in FXR-/- mice (Fig.5A). 
Consistently, plasma leptin levels were lower in FXR-/- mice (Fig.5B). Plasma triglycerides 
were significantly higher in FXR-/- mice upon HFD-feeding (Fig.5C). FXR-/- mice further 
displayed lower blood glucose (Fig.5D) and plasma insulin (Fig.5E) concentrations and 
showed an improved glucose tolerance (p<0.0001; 2way-ANOVA) (Fig.5F and G). Hence, 
similar as in ob/ob mice, FXR-deficiency protects from diet-induced obesity and insulin 
resistance. 
To determine the contribution of hepatic FXR to the protection from diet-induced obesity and 
insulin resistance, liver-specific FXR-/- mice (LFXR-/-) and wildtype littermates (LFXR+/+) 
were fed a HFD for 9w. Both LFXR-/- and LFXR+/+ mice developed obesity (Fig.6A) and 
displayed significantly elevated plasma leptin levels upon HFD-feeding (Fig.6B). LFXR-/- 
mice had significantly higher basal plasma triglycerides than LFXR+/+ littermates but were 
unaffected by HFD-feeding (Fig.6C). HFD-fed LFXR-/- and LFXR+/+ mice became insulin 
resistant displaying hyperglycemia (p<0.0001; 2way-ANOVA) (Fig.6D) and elevated plasma 
insulin levels (Fig.6E). In addition, the diet-induced glucose intolerance was similar in both 
genotypes (Fig.6F and 6G). These findings indicate that liver-specific FXR-deficiency does 
not protect from diet-induced obesity and insulin resistance.  
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Modulation of BA metabolism by sequestration does not affect glucose homeostasis in FXR-/-
ob/ob mice.  
FXR-deficiency led to elevated plasma BA concentrations in genetic (394±86µM vs. 
44±13µM, p<0.001) and diet-induced obesity (119±50µM vs. 22±6µM). Since BA exert 
regulatory functions independent of FXR (17), we evaluated whether this increase may 
account for the observed alteration of body weight and glucose homeostasis.  
The increased availability of plasma BA may lead to the activation of the TGR5 signaling 
pathway subsequently increasing energy expenditure in brown adipose tissue (BAT) (18). 
However, the expression of the TGR5 target genes UCP1 and D2 was decreased or 
unchanged, respectively, in BAT of FXR-/-ob/ob compared to FXR+/+ob/ob mice (Fig.7A), 
indicating that TGR5 activity was not induced. 
To assess whether reducing the elevated plasma BA levels in FXR-/-ob/ob mice would affect 
glucose homeostasis, the BAS colesevelam was administered to FXR-/-ob/ob and FXR+/+ob/ob 
mice for 3w. Colesevelam successfully reduced plasma BA concentrations in both genotypes 
by around 80% already within 9d of treatment (Fig.7B). Body weight slightly but significantly 
increased with colesevelam treatment only in FXR-/-ob/ob mice (Fig.7C). Colesevelam 
decreased blood glucose levels in FXR+/+ob/ob, but not FXR-/-ob/ob mice (Fig.7D). The 
glucose intolerance observed in untreated FXR+/+ob/ob mice improved upon colesevelam 
treatment, whereas such effect was not observed in FXR-/-ob/ob mice (Fig.7E and 7F). 
However, both genotypes displayed increased plasma insulin concentrations upon treatment 
(Fig.7G). Since BAS may lower glycemia by activating the incretin system (23), the 
expression of implicated intestinal genes was measured (Supplementary Table2). The 
expression of proglucagon, coding for GLP-1, and ProGIP, coding for GIP, were induced and 
repressed, respectively, by FXR-deficiency. However, only PC1/3, the enzyme activating both 
incretins, was moderately induced by colesevelam in FXR+/+ob/ob mice, unlikely explaining 
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the observed improvement of glucose homeostasis. Thus, reducing plasma BA concentrations 
had no effect on glucose homeostasis in the absence of FXR, suggesting that the alterations of 
glucose metabolism observed in FXR-deficiency are not mediated by circulating BA. 
 
FXR-deficiency differentially affects the abundance of long- and medium-chain triglyceride 
species in adipose tissue of lean and ob/ob mice. 
FXR-deficiency improves glucose homeostasis in obesity, due at least in part to an increase in 
adipose tissue insulin sensitivity. To investigate changes in adipose tissue lipid composition 
linked to FXR-deficiency before the metabolic phenotype fully develops, high-resolution 
lipidomics was performed in subcutaneous adipose tissue from 6w-old lean and ob/ob (obese) 
FXR-/- and FXR+/+ mice. 
Overall, 133 lipid species were quantified. Total phospholipid and sphingomyelin content was 
significantly lower in obese than in lean mice, whereas total triglycerides were similar 
(Supplementary Fig.1). These lipid classes were unaffected by FXR-deficiency. Of interest, a 
number of triglyceride species was differentially affected by FXR-deficiency in lean and 
obese mice. The concentration of medium-chain triglycerides with a high saturation level was 
significantly higher in obese than lean FXR+/+ mice (Fig.8A-C) and tended to increase by 
FXR-deficiency in both. In contrast, long-chain, unsaturated triglycerides were also 
significantly elevated in obese compared to lean FXR+/+ mice, however increased by FXR-
deficiency in lean but decreased in obese mice (Fig.8D-F). Further, long-chain triglycerides 
containing few double-bounds, which were similar between lean and obese FXR+/+ mice, only 
decreased by FXR-deficiency in lean mice (Fig.8G-I). 
PLS/D analysis revealed that the global subcutaneous adipose tissue lipid profiles clustered 
according to their genotype (Fig.8J). Lipid profiles are significantly different between lean 
and obese mice whether deficient or not for FXR, visualized as a clear separation by the latent 
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variable (LV)1 plotted on the x-axis. Interestingly, the LV2 demonstrated an additional 
separation of lean FXR+/+ and obese FXR-/- from lean FXR-/- and obese FXR+/+ mice, 
indicating that FXR-deficiency modulates lipid profiles in an opposite manner in the lean 
versus obese background. 
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Discussion 
The nuclear receptor FXR is a metabolic regulator which controls BA and lipid as well as 
glucose and energy metabolism (2). FXR can exert direct transcriptional control or indirectly 
influence metabolic pathways by modulating the homeostasis of BA, which control 
metabolism also independent of FXR (17). The characteristics of FXR-/- mice - dyslipidemia 
(7-9), transient hypoglycemia upon fasting (8,10), peripheral insulin resistance (8,13) and 
reduced adipose tissue mass (8,15) - reflect the importance of FXR for the maintenance of 
metabolic homeostasis. Yet, the impact of FXR-deficiency on obesity and associated 
metabolic disorders has not been assessed. In the current study we demonstrate, that FXR-
deficiency in murine models of genetic and diet-induced obesity attenuated weight gain by 
reducing adipose tissue mass. FXR-deficiency further improved glucose homeostasis by 
enhancing peripheral glucose disposal and increasing adipose tissue insulin sensitivity. This 
improvement is not mediated by hepatic FXR, since liver insulin sensitivity was unchanged 
and liver-specific FXR-/- mice were not protected from diet-induced obesity and insulin 
resistance. The administration of the BAS colesevelam, which reduced the elevated plasma 
BA levels resulting from FXR-deficiency in obesity, further revealed that the improved 
glucose homeostasis was independent of BA-mediated pathways. FXR-deficiency thus exerts 
a beneficial effect on body weight development and glucose homeostasis in obesity. 
FXR-/- mice display peripheral insulin resistance, but reported results on the liver are 
contradicting (8,13,31). Surprisingly, we observed an improvement of glucose homeostasis by 
FXR-deficiency in genetic and diet-induced obesity, revealing a differential role for FXR in 
glucose homeostasis in basal (lean) and challenged (obese) metabolic conditions. The 
reduction of hyperglycemia in FXR-/-ob/ob mice resulted from an increased peripheral 
glucose disposal associated with an improved adipose tissue insulin sensitivity. This suggests 
that FXR in adipose tissue contributes to the dysregulation of glucose metabolism in obesity. 
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Hypertrophic adipocytes develop insulin resistance (32). Hence the reduced adipocyte size in 
FXR-/-ob/ob mice (16) might explain the increased insulin sensitivity. In addition to adipose 
tissue, skeletal muscle is the main peripheral tissue accounting for glucose uptake. However, 
the insulin signaling response in skeletal muscle was unaffected by FXR-deficiency. 
Moreover, FXR is not expressed in skeletal muscle (8) and muscle mass strongly reduced in 
genetic obesity. We can therefore exclude the involvement of skeletal muscle in the FXR-
deficiency-mediated changes of glucose homeostasis.  
FXR exerts a key function in the control of hepatic glucose and lipid metabolism (2). In 
hepatic insulin resistance, increased endogenous glucose production contributes to 
hyperglycemia and the continuous insulin-mediated activation of lipogenesis leads to 
hyperlipidemia and may cause a fatty liver (32). In contrast to adipose tissue, FXR-deficiency 
did not improve hepatic insulin sensitivity in genetic obesity and liver-specific FXR-
deficiency did not protect from diet-induced insulin resistance, a rather surprising result 
regarding the importance of hepatic FXR for the metabolic control of lean mice. Further, 
hepatic steatosis often associated with hepatic insulin resistance increased in FXR-/-ob/ob 
mice due to a repression of β-oxidation. Moreover, the repression of hepatic LPL cofactors 
led to an impaired intravascular triglyceride clearance resulting in elevated plasma 
triglycerides. Overall, the changes in lipid metabolism appear to be primarily due to altered 
liver function, while the results on insulin sensitivity emphasize a role for non-hepatic FXR in 
the dysregulation of glucose homeostasis in obesity - most probably in adipose tissue. 
Several studies have shown that FXR controls adipocyte differentiation and function 
(8,15,16). FXR expression occurs early and transiently during adipocyte development, 
inhibiting the Wnt/β-catenin pathway, thus allowing optimal PPARγ activation (16). Since the 
lack of hepatic FXR does not seem to mediate the improvement of glucose homeostasis in 
obesity, it would be of great interest to study adipose tissue-specific FXR-deficiency in 
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obesity. Unfortunately, in the currently available mouse models Cre recombinase expression 
is driven by promoters from late and/or non-specific adipocyte genes (i.e. adiponectin or aP2), 
rendering them inappropriate to study the influence of genes acting earlier in the 
differentiation process, such as FXR. 
FXR-deficiency in obesity was associated with elevated plasma BA levels. BA have been 
reported to improve glucose homeostasis independent of FXR by TGR5-mediated stimulation 
of GLP-1 secretion (19,20). The administration of the BAS colesevelam to ob/ob mice 
successfully reduced plasma BA concentrations, but had no effect on glucose homeostasis in 
the absence of FXR. Thus, elevated circulating BA in FXR-deficiency do not mediate the 
observed improvement in glucose homeostasis. BAS improve glycemic control in type 2 
diabetes, partly via a TGR5-mediated increase of GLP-1 secretion (22,23). The observed 
FXR-dependent improvement of glycemic control by colesevelam in ob/ob mice suggests that 
FXR-mediated pathways contribute to the beneficial effect of BAS. 
Contradictory to our observation that FXR-deficiency is beneficial for glucose homeostasis in 
obesity, FXR activation has been shown to improve insulin resistance in rodent models of 
diabetes (8,31,33). The reason for this apparent inconsistency is currently unclear. However, 
the pharmacological activation of a nuclear receptor does not always and necessarily have the 
opposite effects than the knockout of its expression. The specific pharmacodynamics of the 
used compounds may also affect FXR in tissue-specific manner (sBARM effect), whereas our 
study focused on whole-body FXR-deficiency. 
Both genetic and diet-induced obesity are attenuated in the absence of FXR. FXR-deficiency 
leads to reduced adipose tissue mass (8,15,16) and adipocyte size (16) in lean and ob/ob mice 
limiting energy storage capacity. Since food intake and energy expenditure only tended to 
decrease in FXR-/-ob/ob mice, the decreased adipose tissue mass most likely accounts for the 
reduced weight gain. With regard to the moderate decrease in energy expenditure, a central 
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effect of FXR seems unlikely, additionally since FXR expression in hypothalamus is only 
very weak (34). Further, the lack of TGR5 target gene induction in BAT of FXR-/-ob/ob mice 
argues against the implication of a TGR5-cAMP-D2-mediated mechanism (18). If the reduced 
body weight was a direct effect of a decreased food intake in the hyperphagic model of FXR-/-
ob/ob mice, the hepatic triglyceride content would have also been reduced and not elevated as 
observed.  
Interestingly, the analysis of adipose tissue lipid profiles by lipidomics revealed a differential 
alteration of certain triglyceride classes in lean and obese mice by FXR-deficiency, e.g. long-
chain, unsaturated triglycerides are lowered by FXR-deficiency in obese but increased in lean 
mice. This observation demonstrates that FXR-deficiency specifically and opposingly affects 
adipose tissue metabolism as it does glucose homeostasis in lean and obese conditions. 
Overall, in contrast to lean mice, FXR-deficiency in obesity improves energy and glucose 
homeostasis. The selective inhibition of FXR activity may thus be an appealing option for the 
therapy of obesity and the related dysregulation of glucose homeostasis. 
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Figure 1. FXR-deficiency attenuates weight gain in ob/ob mice. 
A. FXR+/+ob/ob (white bars or diamonds) and FXR-/-ob/ob mice (black bars or triangles) 
(n=9-10/group) were monitored weekly for body weight. Significance of the overall effect of 
genotype (p<0.0001) and age (p<0.0001) as well as their interaction (p<0.0001) was 
calculated by 2way-ANOVA. B. Body composition was assessed by dual x-ray 
absorptiometry in twenty week old mice (n=9-10/group). C. O2-consumption (VO2) and D. 
CO2-production (VCO2) were determined in twenty week old mice (n=5/group) individually 
housed in metabolic cages. Values are means±SEM. Differences between genotypes over time 
were analyzed by 2way-ANOVA and Bonferroni post-hoc test, differences between 
genotypes were calculated by Mann-Whitney test (*0.05, **<0.01, ***<0.001). 
 
Figure 2. FXR-deficiency improves glucose homeostasis in ob/ob mice. 
A. Fasting blood glucose was measured weekly in FXR+/+ob/ob (white bars or diamonds) and 
FXR-/-ob/ob mice (black bars or triangles) (n=9-10/group). Significance of the overall effect 
of the genotype (p<0.0001) was calculated by 2way-ANOVA. B. Plasma insulin was 
determined in twelve week old mice (n=9-10/group). C. Blood glucose excursion and D. 
integrated AUC after administration of an i.p. glucose bolus (1g/kg glucose) were measured in 
twelve week old mice (n=9-10/group). Significance of the overall effect of genotype 
(p<0.0001) and time (p<0.0001) was calculated by 2way-ANOVA. E. Metabolic clearance 
rate (MCR) was determined by stable isotope dilution in fourteen week old mice (n=5-
6/group). F. Blood glucose excursion and G. iAUC after administration of an i.p. insulin 
bolus (2IU insulin/kg) were measured in thirteen week old mice (n=9-10/group). Significance 
of the overall effect of genotype (p<0.0001) and time (p<0.0001) was calculated by 2way-
ANOVA. H. Pancreases of twenty week old mice (n=9-10/group) were sectioned, submitted 
to Papanicolaou staining and I. the mean surface of the islets of Langerhans was quantified. 
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Arrows indicate islets of Langerhans (scale bar =1mm). Values are means±SEM. Differences 
between genotypes over time were analyzed by 2way-ANOVA and Bonferroni post-hoc test, 
differences between genotypes were calculated by Mann-Whitney test (*0.05, **<0.01, 
***<0.001). 
 
Figure 3. FXR-deficiency improves adipose tissue, but not hepatic insulin sensitivity in 
ob/ob mice. 
A. Thirteen week old female FXR+/+ob/ob (white bars) and FXR-/-ob/ob mice (black bars) 
(n=4/group) were injected with either saline or insulin. Phosphorylation of Akt at Serine473 
and total Akt protein expression was determined by Western Blot and the signal quantified. B. 
Gene expression was measured by qPCR and C. triglyceride content was determined 
enzymatically in livers of twenty week old mice (n=9-10/group). Values are means±SEM. 
Differences between genotypes were calculated by Mann-Whitney test (*<0.05, **<0.01, 
***<0.001). WAT, white adipose tissue; pAkt, Serine473-phosphorylated Akt; TG, 
triglyceride. 
 
Figure 4. FXR-deficiency in ob/ob mice results in the accumulation of plasma 
triglycerides. 
A. and B. Lipid parameters were measured in plasma of twelve week old FXR+/+ob/ob (white 
bars or diamonds) and FXR-/-ob/ob mice (black bars or triangles) (n=9-10/group). C. 
Lipoprotein profiles were determined in plasma pools of thirteen week old mice. D. VLDL 
production was assessed in thirteen week old female mice (n=8-10/group) by measuring 
plasma triglyceride concentrations subsequent to Tyloxapol injection. E. Gene expression was 
measured by qPCR in livers of twenty week old mice (n=9-10/group). Values are 
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means±SEM. Differences between genotypes were calculated by Mann-Whitney test 
(***<0.001). FFA, free fatty acid; TG, triglyceride; IDL, intermediary density lipoprotein. 
 
Figure 5. FXR-deficiency protects from diet-induced obesity and insulin resistance. 
FXR+/+ (white bars or diamonds) and FXR-/- mice (black bars or triangles) (n=7-11/group) 
were fed a high-fat diet (HFD) for twenty weeks. A. Body weight was monitored weekly 
(n=7-11/group). Significance of the overall effect of genotype (p<0.0001) and age (p<0.0001) 
as well as their interaction (p<0.0001) was calculated by 2way-ANOVA. B. Plasma leptin, C. 
plasma TG, D. blood glucose and E. plasma insulin were determined at the end of the feeding 
period (n=4-9/group). F. Blood glucose excursion and G. integrated AUC after administration 
of an i.p. glucose bolus (1g/kg glucose) were measured at the end of the feeding period (n=6-
9/group). Significance of the overall effect of genotype (p<0.0001) and time (p<0.0001) was 
calculated by 2way-ANOVA. Values are means±SEM. Differences between genotypes over 
time were analyzed by 2way-ANOVA and Bonferroni post-hoc test, differences between 
genotypes were calculated by Mann-Whitney test (*<0.05, **<0.01, ***<0.001). TG, 
triglyceride. 
 
Figure 6. Liver-specific FXR-deficiency does not protect from diet-induced obesity and 
insulin resistance. 
LFXR-/- mice and LFXR+/+ littermates (n=7-12/group) were fed a high-fat diet (HFD) or a 
control diet (CD) for ten weeks (LFXR+/+CD = vertically-hatched bars or circles; LFXR-/-CD 
= diagonally-hatched bars or squares; LFXR+/+HFD = white bars or diamonds; LFXR-/-HFD = 
black bars or triangles). A. Body weight was monitored weekly. Significance of the effect of 
diet (p<0.0001) and age (p<0.0001) as well as their interaction (p<0.0001) was calculated by 
2way-ANOVA. B. Plasma leptin and C. plasma TG were determined at the end of the feeding 
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period. D. Fasting blood glucose was measured weekly. Significance of the overall effect of 
diet (p<0.0001) and age (p<0.0001) as well as their interaction (p=0.0217) was calculated by 
2way-ANOVA. E. Plasma insulin was measured after six weeks of feeding. F. Blood glucose 
excursion and G. integrated AUC after administration of an i.p. glucose bolus (1g/kg glucose) 
were measured after five weeks of feeding (n=6/group). Values are means±SEM. Differences 
between diet groups over time were analyzed by 2way-ANOVA and Bonferroni post-hoc test, 
differences between genotypes or diet groups were calculated by Mann-Whitney test 
(*compares genotypes of the same diet group; $ compares diet groups for LFXR+/+; § 
compares diet groups for LFXR-/-; $ or §<0.05, ** or $$ or §§ <0.01, $$$ or §§§<0.001). TG, 
triglyceride. 
 
Figure 7. Modulation of bile acid metabolism does not affect glucose homeostasis in 
FXR-/-ob/ob mice.  
Ten week old FXR+/+ob/ob and FXR-/-ob/ob mice were administered 2% colesevelam mixed 
in the diet or plain diet for three weeks (n=13/group) (FXR+/+ob/ob control = white bars or 
diamonds; FXR+/+ob/ob treated = vertically-hatched bars or circles; FXR-/-ob/ob control = 
black bars or triangles; FXR-/-ob/ob treated = diagonally-hatched bars or squares). A. TGR5 
target gene expression was measured by qPCR in BAT of twenty week old mice (n=9-
10/group). B. Plasma bile acids were measured after nine days of treatment. C. Body weight 
was monitored weekly during the treatment period. Significance of the overall effect of 
treatment (p<0.0001) and age (p=0.0002) was calculated by 2way-ANOVA. D. Fasting blood 
glucose was determined weekly during the treatment period. E. Blood glucose excursion and 
F. integrated AUC after administration of an i.p. glucose bolus (1g/kg glucose) were 
measured at the end of the treatment period. G. Plasma insulin was measured at the end of the 
treatment period. Values are means±SEM. Differences between treatment groups over time 
Page 27 of 38 Diabetes
 27 
were analyzed by 2way-ANOVA and Bonferroni post-hoc test, differences between 
genotypes or treatment groups were calculated by Mann-Whitney test (*compares genotypes 
of the same treatment group; $ compares treatment groups of the same genotype; *or $<0.05, 
**or $$<0.01, ***or $$$<<0.001). BAT, brown adipose tissue; BA, bile acids. 
 
Figure 8. FXR-deficiency differentially affects the abundance of long-chain, unsaturated 
triglyceride species in adipose tissue of lean and obese mice.  
Lipidomics analysis was performed in white adipose tissue of six week old FXR+/+ob/ob, 
FXR-/-ob/ob mice as well as lean FXR+/+ and FXR-/- littermates (Lean FXR+/+ = white bars or 
vertically-hatched circles; Lean FXR-/- = black bars or diagonally-hatched squares; Obese 
FXR+/+ = white bars or diamonds; Obese FXR-/- = black bars or triangles). Representative data 
for A.-C. medium-chain triglycerides with a high saturation level, D.-F. long-chain, highly 
unsaturated triglycerides and G.-I. long-chain triglycerides containing few double-bounds. J. 
PLS/DA of all measured lipid species. Values are means±SEM. Differences between 
genotypes were calculated by 1way-ANOVA and Student’s t-test (*compares the effect of 
leptin-deficiency; $ compares the effect of FXR-deficiency; *or $<0.05, **or $$<0.01, ***or 
$$$<0.001). TG, triglyceride; LV, latent variable. 
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Supplementary Figure 1. Lipidomics analysis of lipid classes in adipose tissue of FXR-deficient lean and ob/ob 
mice. 
Lipidomics analysis was performed in white adipose tissue of six week old FXR+/+ob/ob (white bars), FXR-/-ob/ob mice 
(black bars) as well as lean FXR+/+ and FXR-/- littermates. Content of A. total phospholipids, B. total sphingomyelins and 
C. total triglycerides. Values are means±SEM. Differences between genotypes were calculated by 1way-ANOVA and 
Student’s t-test (*compares the effect of leptin-deficiency; ***<0.001).
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28S
Apoc2 (apoCII)
Apoa5 (apoAV)
Srebf1 (Srebp1c)
Acaca (Acc1)
Fasn (Fas)
Scd1
Ppara
Cpt1a
Acacb (Acc2)
Ucp1
Dio2 (D2)
Gcg (Proglucagon)
Pcsk1 (PC1/3)
ProGIP
Gene                                    
CTTACCAAAAGTGGCCCACTA
TGCTCATGGCCGCCGAGCTT
GTTCTCCTGTGCCAGCTTCTG
ATAGGGGGCGTCAAACAGG
CATACTGATCTGCCAAGACCTG
ACAGGTACACTTTTCCGCTCAC
CAGAGTGTATCGCAAGAAGGTG
CAGGCCGATCTCCACAGCAAATTA
CAGTGCTGTCATGCGTTGG
CATACTGATCTGCCAAGACCTG
TTTTCAGCTGTTCAAAGCACA
GCCCCATCAGCGGTCTTCTCCGA
GGCGACTTCTTCTGGGAAGT
TGTGTGATTCCACTCCAAGCCA
TGAAAGTCCCCTCTGCGTAC
Reverse
AAACTCTGGTGGAGGTCCGT
CTGCTGGGCACGGTGCAGGG
TGGCTGCAGTCATCACTTGG
ATCGGCGCGGAAGCTGTCGGGG
CGACAAGTGCAGAGTGAGATTC
CAGGCCACTATACTACCCAAGA
AGAAGCTGGTGATGTTCCAGAG
ATCGCGTACGGCAATGGCTTTA
CATCATGACTATGCGCTACTC
CGACAAGTGCAGAGTGAGATTC
CTGCCAGGACAGTACCCAAG
GAAGGGCTGCGCTGTGTCTGGA
ATTGCCAAACGTCATGATGA
GTGACGTGGGCTGAACAACAGTAT
CCTCCTGGAAGAGCTAAGAA
NR_003279.1
NM_009695.3
NM_080434
NM_11480
NM_133360
NM_007988
NM_009127
NM_011144
NM_013495
NM_133904
NM_009463.2
NM_010050.2
NM_008100 
NM_000439
NM_008119
ForwardNCBI
Supplementary Table 1. Primer pairs used for quantitative RT-PCR.
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1.63 ± 0.37
2.01 ± 0.35$
0.38 ± 0.04$ $
FXR+/+ob/ob
treated
4.23 ± 0.66**
1.57 ± 0.20
0.43 ± 0.08*
FXR-/-ob/ob
control
2.31 ± 0.25$
2.18 ± 0.24
0.27 ± 0.03
1.00 ± 0.24
1.00 ± 0.13
1.00 ± 0.03
Proglucagon
PC1/3
ProGIP
FXR-/-ob/ob
treated
FXR+/+ob/ob
control
Gene
Supplementary Table 2. Influence of FXR-deficiency in ob/ob mice on intestinal gene expression after treatment 
with colesevelam.
Ten week old FXR+/+ob/ob and FXR-/-ob/ob mice were administered 2% colesevelam mixed in the diet or plain diet for 
three weeks (n=13/group). Gene expression was measured by qPCR in the intestine. Values are means±SEM. 
Differences between genotypes or treatment groups were calculated by Mann-Whitney test (*compares genotypes of the 
same treatment group; $ compares treatment groups of the same genotype; *or $<0.05, **<0.01).
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